[PDF][PDF] Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor …
L Rydén, K Jirström, PO Bendahl… - Journal of Clinical …, 2005 - researchgate.net
L Rydén, K Jirström, PO Bendahl, M Fernö, B Nordenskjöld, O Stål, S Thorstenson…
Journal of Clinical Oncology, 2005•researchgate.netPurpose Vascular endothelial growth factor A (VEGF-A) and vascular endothelial growth
factor receptor 2 (VEGFR2) are often coexpressed in breast cancer, and potentially affect
cellular pathways and key proteins such as the estrogen receptor (ER) targeted by
endocrine treatment. We therefore explored the association between adjuvant tamoxifen
treatment in breast cancer and expression of VEGF-A and VEGFR2, as well as human
epidermal growth factor receptor 2 (HER2), which represents a candidate gene product …
factor receptor 2 (VEGFR2) are often coexpressed in breast cancer, and potentially affect
cellular pathways and key proteins such as the estrogen receptor (ER) targeted by
endocrine treatment. We therefore explored the association between adjuvant tamoxifen
treatment in breast cancer and expression of VEGF-A and VEGFR2, as well as human
epidermal growth factor receptor 2 (HER2), which represents a candidate gene product …
Conclusion
Tumor-specific expression of VEGFR2 was associated with an impaired tamoxifen effect in hormone receptor–positive premenopausal breast cancer. Tamoxifen in combination with VEGFR2 inhibitors might be a novel treatment approach for VEGFR2-expressing breast cancer, and such a treatment might restore the tamoxifen response.
researchgate.net